Loading organizations...
§ Private Profile · Duisburg, Nordrhein-Westfalen, Germany
Biopharmaceutical company developing novel antibody-drug conjugate (ADC) therapeutics for high-need solid tumors in oncology.
Emergence Therapeutics is a specialized biopharmaceutical company developing novel antibody-drug conjugate therapeutics for high-need solid tumors, based in Duisburg, Germany. The organization focuses on treating cancers such as bladder, triple-negative breast, lung, and ovarian cancer through its lead candidate, ETx-22, which targets Nectin-4 on malignant cells to improve dosing efficacy and patient safety. Prior to its exit, the enterprise secured $97.79 million in total venture funding, highlighted by an €87 million Series A round in December 2021 backed by institutional investors including Heidelberg Pharma. In June 2023, the business and its intellectual property were fully acquired by pharmaceutical corporation Eli Lilly and Company, leading the executive team to subsequently partner with Pontifax Venture Capital on a new corporate entity. Emergence Therapeutics was originally founded in 2019 by co-founders Jack Elands, Xavier Preville, and Carsten Dehning.
Emergence Therapeutics has raised $98.0M across 1 funding round.
Emergence Therapeutics has raised $98.0M in total across 1 funding round.
Emergence Therapeutics has raised $98.0M across 1 funding round. Most recently, it raised $98.0M Series A in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $98M Series A | Pontifax Venture Capital | Andera Partners, EQT Life Sciences, Kurma Partners, Olivier Martinez, Gründerfonds Ruhr, Roger Franklin, High Tech Grunderfonds, Marek Kozlowski, PHD Msceng, ROY Amariglio, Matthew Hammond | Announced |
Emergence Therapeutics is a European biopharmaceutical company specializing in the development of novel antibody-drug conjugates (ADCs) aimed at treating high-need solid cancers that are difficult to treat with existing therapies. Their lead product candidate, ETx-22, targets the Nectin-4 protein, which is overexpressed in bladder cancer and other malignancies, with the goal of improving selectivity and reducing toxic side effects compared to current ADC therapies. Founded in 2019 and based in Duisburg, Germany, Emergence Therapeutics has demonstrated strong growth momentum, raising nearly $98 million before being acquired by Eli Lilly in 2023, reflecting its promising pipeline and strategic value in oncology drug development[1][2][3][5].
Emergence Therapeutics was founded by a team with strong scientific and industry backgrounds, leveraging antibody-related intellectual property licensed from the University of Aix-Marseille and toxin-related IP from Heidelberg Pharma. The company emerged from a recognition that while ADCs have shown potential in cancer treatment, significant improvements were needed in the antibody, toxin, and linker components to enhance efficacy and safety. Early traction included a successful €87 million Series A funding round in 2021 and strategic partnerships, such as a $360 million ADC-focused deal with Synaffix, culminating in its acquisition by Eli Lilly, which underscores the company’s rapid evolution and validation within the oncology biotech sector[1][3][5].
Emergence Therapeutics is positioned at the forefront of the growing trend toward precision oncology and targeted cancer therapies, specifically leveraging ADCs to improve treatment outcomes for solid tumors. The timing is critical as ADCs are gaining traction due to their ability to deliver cytotoxic agents directly to cancer cells, minimizing systemic toxicity. Market forces such as increasing cancer incidence, demand for more effective therapies, and advancements in antibody engineering favor Emergence’s approach. By advancing ADC technology, Emergence contributes to the broader ecosystem by pushing innovation boundaries and fostering collaborations between academia, biotech startups, and large pharmaceutical companies[3][5].
Following its acquisition by Eli Lilly, Emergence Therapeutics is poised to accelerate the clinical development of its ADC candidates, potentially expanding indications beyond bladder cancer to other solid tumors. The evolving landscape of oncology, with increasing emphasis on targeted and personalized therapies, will shape Emergence’s trajectory. Continued innovation in ADC design and improved safety profiles will be key trends influencing their journey. As part of a major pharmaceutical company, Emergence’s influence is likely to grow, contributing to new cancer treatment paradigms and potentially improving patient outcomes on a global scale[1][5].
Emergence Therapeutics has raised $98.0M in total across 1 funding round.
Emergence Therapeutics's investors include Pontifax Venture Capital, Andera Partners, EQT Life Sciences, Kurma Partners, Olivier Martinez, Gründerfonds Ruhr, Roger Franklin, High-Tech Grunderfonds, Marek Kozlowski, PhD MScEng, Roy Amariglio, Matthew Hammond.